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Abstract
Background: The phenotypic severity of congenital muscular dystrophy-dystroglycanopathy (MDDG) syndromes
associated with aberrant glycosylation of α-dystroglycan ranges from the severe Walker-Warburg syndrome or
muscle-eye-brain disease to mild, late-onset, isolated limb-girdle muscular dystrophy without neural involvement.
However, muscular dystrophy is invariably found across the spectrum of MDDG patients.
Methods: Using linkage mapping and whole-exome sequencing in two families with an unexplained
neurodevelopmental disorder, we have identified homozygous and compound heterozygous mutations in B3GALNT2.
Results: The first family comprises two brothers of Dutch non-consanguineous parents presenting with mild ID and
behavioral problems. Immunohistochemical analysis of muscle biopsy revealed no significant aberrations, in line with the
absence of a muscular phenotype in the affected siblings. The second family includes five affected individuals from an
Iranian consanguineous kindred with mild-to-moderate intellectual disability (ID) and epilepsy without any notable
neuroimaging, muscle, or eye abnormalities. Complementation assays of the compound heterozygous mutations
identified in the two brothers had a comparable effect on the O-glycosylation of α-dystroglycan as previously reported
mutations that are associated with severe muscular phenotypes.
Conclusions: In conclusion, we show that mutations in B3GALNT2 can give rise to a novel MDDG syndrome presentation,
characterized by ID associated variably with seizure, but without any apparent muscular involvement. Importantly,
B3GALNT2 activity does not fully correlate with the severity of the phenotype as assessed by the complementation assay.
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Background
Congenital muscular dystrophy-dystroglycanopathy (MDDG)
syndromes are a group of inherited disorders with a broad
clinical phenotype [1]. The most severe form is Walker-
Warburg syndrome (WWS), which has an onset at birth
and is characterized by severe muscular dystrophy,
cobblestone lissencephaly, cerebellar abnormalities, hydro-
cephalus, and eye malformations. Patients with muscle-
eye-brain disease (MEB) and Fukuyama congenital mus-
cular dystrophy (FCMD) have a similar but less severe
phenotype. The mildest form of MDDG syndrome is
limb-girdle muscular dystrophy (LGMD), which has a
later age of onset and in which only a small proportion of
patients present with mild structural brain abnormalities
[2, 3] or dilated cardiomyopathy [4]. However, muscular
dystrophy is the hallmark of all MDDG syndromes
described so far.
MDDG syndromes are caused by defective O-
glycosylation of α-dystroglycan (α-DG), leading to reduced
α-DG-laminin binding in the extracellular matrix [5, 6].
Mutations in DAG1 encoding α-DG and β-DG, and in 17
other genes, encoding proteins involved in the O-
glycosylation pathway, cause different forms of MDDG syn-
drome [7–9].
Thus far, ten patients with mutations in the B3GALNT2
(NM_152490.4) have been described [10–12]. These
patients have various combinations of missense and trun-
cating mutations associated with variable but consistently
severe phenotypes and with congenital muscular dys-
trophy in all cases. In this work, we describe two families
with seven affected individuals that present with a novel
atypical and very mild form of MDDG resulting from
compound heterozygous and homozygous mutations,
respectively, in B3GALNT2. In addition, complementation
assays were performed to analyze the effect of the various
mutations on the O-glycosylation of α-DG.
Methods
Patients
The patients from family A were ascertained in a large co-
hort study comprising individuals with unexplained intel-
lectual disability (ID) at the Department of Human
Genetics of the Radboud University Medical Center in
Nijmegen, the Netherlands, where they had a thorough
genetic diagnostic evaluation [13, 14]. Members of family
B were recruited through Pardis Genetic laboratory in
Mashhad, Iran. The parents consented to this study and
the study was approved by the local ethical committees.
Genetic study
DNA was extracted from peripheral blood, using stand-
ard procedures. For Family A, exome sequencing was
carried out for both the affected brothers. Exome enrich-
ment was performed using the SureSelectXT Human All
Exon 50 Mb Kit (Agilent, Santa Clara, CA, USA). DNA
samples were multiplexed and sequenced using the
SOLiDTM 4 System, leading to 6.09 Gb and 7.22 Gb of
mappable sequence, respectively. Read mapping and
variant calling was performed with SOLiD bioscope soft-
ware v1.3 using hg19 as the human reference genome.
For Family B, a genome-wide single nucleotide poly-
morphism (SNP) genotyping analysis was first under-
taken in four affected (IV:1, IV:3, IV:6, V:2) and two
unaffected individuals (IV:7; IV:9) using the Illumina
HumanCytoSNP-12 v2.1 chip array (330 K markers) for
autozygosity mapping. This was followed by whole ex-
ome sequencing (WES) of genomic DNA from proband
(V:2) performed at Otogenetics Corporation (Norcross,
GA, USA) using the Agilent SureSelect Human All
ExonV4 (51 Mb) enrichment kit with a paired-end (2 ×
100) protocol at a mean coverage of 30X. Reads were
aligned to genome assembly hg19 with the Burrows-
Wheeler Aligner (BWA, V.0.5.87.5).
Biochemical analysis
Staining for α-DG (IIH6; mouse monoclonal IgG
antibody, 1:1000, Millipore) was carried out on pa-
tient skeletal muscle sections as described previously
[15].
Cell culture
Human haploid HAP1 cells [16] were cultured in
Iscove’s modified Dulbecco’s medium (IMDM, Gibco)
supplemented with 10% fetal bovine serum and 1% Peni-
cillin/streptomycin/L-glutamine (Gibco) at 37 °C under
5% CO2 atmosphere.
Complementation of B3GALNT2-deficient HAP1 cells
B3GALNT2 complementary DNA (cDNA) was cloned
into a retroviral expression vector, pBabe-puro, using
EcoRI and SalI restriction sites as previously described
[17]. Mutant constructs were obtained by site-directed-
mutagenesis using Phusion® High Fidelity DNA Polymer-
ase (New England Biolabs), Q-solution (Qiagen), and five
pairs of primers (primer sequences available upon
request): viruses expressing wild-type (WT) and mutant
B3GALNT2 were produced in 293 T cells and used to
infect HAP1 B3GALNT2-deficient cells as described
previously [10].
Flow cytometry analysis
HAP1 WT, B3GALNT2-deficient, and complemented
cells were incubated with IIH6-C4 antibody (Millipore),
followed by incubation with goat anti-mouse Alexa
Fluor568 antibody (Invitrogen). Subsequently, the fluor-
escence signal was measured at a BD Fortessa flow
cytometer as described previously [17].
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Results
Patient phenotype
Family A
Patients II-1 and II-3, from a Dutch non-consanguineous
family, are two affected male siblings aged 14 and 8 years
at presentation. They have a healthy brother (Fig. 1a). Pa-
tient II-1 was born after an uncomplicated pregnancy and
birth, with a normal birth weight of 3655 g (50th–75th
centile). He was a very quiet baby. His psychomotor devel-
opment was delayed. Speech development was delayed
more than motor development. He has walked independ-
ently since the age of 21 months. He started to speak his
first words at the age of three years. At the age of 11 years
he still had trouble telling simple stories and was diag-
nosed with dysphasia. He could read at beginners’ level. A
formal intelligence test yielded an IQ of 55. His behavior
was characterized by temper tantrums and features of aut-
ism spectrum disorder. Hearing and vision were normal.
At the age of 10 years 11 months, he had a normal height
(143 cm/20th centile) and weight (34 kg/50th centile) and
a low normal head circumference (52 cm/5th centile).
There were no facial dysmorphic features observed.
Neurological evaluation revealed dysphasia and he had
symmetrical low tendon reflexes, but no further signs of
pyramidal, extrapyramidal, cerebellar, or neuromuscular
problems were observed. Brain magnetic resonance im-
aging (MRI) at the age of three years showed mild bilateral
periventricular white matter signal abnormalities. At the
age of 12 years, brain MRI was repeated and found to be
normal (Fig. 2). The creatine kinase (CK) level was slightly
elevated (187 U/L; normal < 170 U/L). A muscle biopsy in-
cluding spectrin, laminin, and glycosylated α-DG staining
showed an intact muscle structure and no significantly ab-
normal α-DG staining (Fig. 1b). Genome-wide chromo-
somal analysis by 250 K SNP array analysis and a
metabolic screen revealed no abnormalities.
The younger brother, patient II-3, was born after an un-
complicated pregnancy and birth. He had a normal birth
weight of 3495 g (50th centile). His psychomotor develop-
ment was delayed with independent walking after the age of
two years and a severe speech delay with only five single
words at the age of three years. At the age of 5 years
4 months, his speech was only intelligible to his parents and
his articulation was poor. A formal intelligence test showed
a total IQ of 68. He had hyperactive behavior and a need for
structure, but better social interaction than his brother,
though contact was mainly functional. He occasionally dis-
played aggressive behavior and had problems falling asleep.
His attention span was very short. Hearing and vision were
normal. At the age of 5 years 4 months, he had a normal
height (114.5 cm/50th centile), weight (20 kg/50th centile),
and head circumference (51.4 cm/50th centile). He had no
evident facial dysmorphic features. Upon clinical neuro-
logical evaluation intelligibility was poor, but his speech was
not truly dysarthric. He had no signs of pyramidal, extrapyr-
amidal, cerebellar, or neuromuscular dysfunctioning. As with
his brother, genome-wide chromosomal analysis by 250 K
SNP array analysis revealed no abnormalities. Therefore,
both were included in exome sequencing studies assuming
an autosomal recessive or X-linked inheritance pattern.
Family B
This is a large, consanguineous Iranian kindred with five in-
dividuals, three male and two female, aged 3–37 years
across four branches, affected by unexplained autosomal re-
cessive developmental delay (DD), ID, and epilepsy. Similar
to family A, speech is more severely affected than motor
development in the affected members of the family. All the
patients were born after normal pregnancies from healthy
parents who are related. Karyotype analysis by G-banding
and tandem mass spectrometry screening for metabolic dis-
orders as well as Fragile X screening were performed for all
affected individuals and they were normal. Results of brain
computed tomography (CT) scans taken for all the patients
were unremarkable. The results of routine laboratory test-
ing and CK level was within normal range. Physical exam-
ination, dysmorphology examination, and neurological
assessment did not find anything unusual except for cogni-
tion deficiency and history of seizure. The patients did not
have any neurological problems, autistic features, behavioral
abnormalities, nor congenital malformations. Growth pa-
rameters including height, weight, head circumference, and
general health were normal and there were no clinical or
biochemical indications of other systems involvement.
Hearing and ophthalmologic (retina and optic nerve) exam-
inations did not find any defect. None of the patients had
any signs of muscle weakness or muscle atrophy.
The proband (V:2) of the family is a nine-year-old
girl who was born by a Cesarean-section delivery. She
was cyanotic at birth but otherwise normal. She had a
history of seizures starting at the age of 15 days and
was under treatment with Phenobarbital between the
ages of 4 and 8 months. Her EEG result was abnor-
mal at the time, but she is currently seizure-free. She
had psychomotor delay and with physiotherapy she
started to walk at the age of two years. She also had
speech delay (only three-word sentences). After
speech therapy, her speech has improved significantly
and she speaks much better although it is still not
comprehensible. She has mild to moderate ID. Her
formal intelligence test yielded an IQ of < 50 with
need of special education schooling. She is usually a
quiet girl and no behavioral abnormalities were no-
ticed. Brain MRI at the age of 18 months showed
high signal intensity along the periventricular white
matter and leukodystrophy was suggested as a pos-
sible diagnosis. However, at the age of seven years,
brain MRI was repeated and found to be normal.
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Individuals IV:3 and IV:6 are two brothers aged 34 year
and 41 years, respectively, who are maternal uncles of
the proband with mild ID (IQ:50) and epileptic seizures
until the age of five years. Both brothers remain illiterate
past adolescence. However, they are able to take care of
themselves. They have similar clinical presentation. Both
had psychomotor delay and started walking at the age of
2.5 years. They had speech delay and speak with diffi-
culty. The brothers had tonic-clonic generalized seizure
for the first five years of life controlled by treatment.
Individual IV:1 is a 37-year-old man who is dis-
tantly related to the proband with moderate-severe
DD/ID accompanied with recurrent epileptic seizure
developed at infancy and he is currently on
Carbimazole. His IQ is < 50 and he is unable to take
care of himself and is therefore currently institution-
alized. He lacks bladder control and needs assistance
with eating food. He understands his surroundings
and responds well. His speech is poor and he can
only say a few words. His gait is abnormal, character-
ized with tiptoeing with long steps and poor balance
and he needs help with walking. However, he can go
up and down stairs.
Individual V:1 is a 8.5-year-old girl who is a cousin of
the proband and has a similar clinical presentation as
the proband, with seizures, speech impairment, and
mild-to-moderate DD/ID. The DNA samples from this
patient were not available for genetic analysis.
ab
c
f
d
e
Fig. 1 Genetic and biochemical analysis. a, b Pedigrees of the two families showing segregation of the mutated alleles within the families. The
affected individuals are shown as black symbols and the gray symbol shows a 28-year-old individual with only borderline learning difficulty and
attention deficit hyperactivity disorder without epilepsy. Mutant alleles shown by “+” and WT allele shown by “−.” c, e Sections of Sanger sequencing
chromatograms for the mutations, heterozygous, and WT alleles are depicted and location of the alteration is demonstrated in the box. W wildtype, C
carrier, P patient. d Immunohistochemistry of skeletal muscle of patient II-1 showed a minimal reduction of α-DG staining compared to a healthy
control. α-DG staining was performed using the IIH6 antibody, recognizing the laminin-binding glycol-epitope. Spectrin and laminin staining were
performed as control. f Schematic overview of the B3GALNT2 structure and the mutations identified in both families. The duplication leads to a premature
stop codon (*), resulting in a truncated transcript lacking the galactosyltransferase domain. The missense mutations are located on exon 8 and cause
substitution of a strongly conserved residue within the galactosyltransferase domain
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Table 1 summarizes the clinical features of the seven
individuals from the Dutch and Iranian families.
Genetic analysis
Family A
To identify the genetic defect(s) causing the disease in
the affected brothers, exome sequencing was carried out.
Under the assumption that homozygous, compound het-
erozygous, or hemizygous variants are responsible with
inclusion of variants present in ≥ 4 reads and present
in ≥ 80% of all reads (homozygous) or biallelic in 15–
80% of the reads (compound heterozygous) (Table 2),
two potential compound heterozygous mutations in the
B3GALNT2 were identified. The compound heterozy-
gous mutation consists of a duplication of two base pairs
that leads to a premature stop codon (c.822_823dup,
p.Ile276Leufs*26) in exon 7 and a missense mutation
(c.988C > T, p.Arg330Cys) in exon 8. Both mutations
Table 1 Comparison of phenotypes in Dutch and Iranian families
Family A Family B
II-1 II-2 IV:1 IV:6 IV:3 V-2 V:1
Age at last evaluation
(years)
14 8 36 41 34 9 8.5
Gender M M M M M F F
Ancestry Dutch Dutch Iranian Iranian Iranian Iranian Iranian
Consanguinity No No Yes Yes Yes Yes Yes
Weight (kg) 34 (11 years) 20 (5.4 years) 62 60 57 40 32
Height (cm) 143 (11 years) 114.5 (5.4 years) 165 155 160 142 133
Head circumference (cm) 52 (11 years) 51.4 (5.4 years) Normal Normal Normal Normal Normal
Cognition and ID Mild Mild Moderate
to Severe
Mild Mild Mild to Moderate Mild to Moderate
IQ level 55 68 Below 50 ~50 ~50 ~50 ~50
Speech Dysphasia Delayed and
poor
intelligibility
Only a few
words
Delayed Delayed Incomprehensible but
improving
Incomprehensible
Motor function Delayed Delayed Gait
abnormality
Delayed Delayed Delayed Delayed
Epilepsy No No Yes Yes Yes Yes Yes
Muscular abnormality/CK
level
No/slightly elevated No/normal No/normal No/
normal
No/
normal
No/normal No/Not done
Muscle biopsy Normal Not done Not done Not
done
Not
done
Not done Not done
Vision examination Normal Normal Normal Normal Normal Normal Normal
Brain imaging MRI: non-specific white
matter changes that
resolved later
Not done Normal CT
scan
Normal
CT scan
Normal
CT scan
MRI: non-specific white
matter changes that resolved
later
Not done
Fig. 2 T2-weighted MRI of the brain of patient II-1 at the age of 12 years. The images illustrate the normal appearance of the cerebellum and the pons
(a) and the normal signal intensities of the cerebellar and cerebral white matter as well as the normal development of the cerebral cortex (b, c)
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were verified by Sanger sequencing (Fig. 1c). Segregation
analysis in the family showed that the parents carry one
of the mutations each and that the healthy brother
carries only the missense mutation (Fig. 1a). The
B3GALNT2 mutations were the only variants identified
by exome sequencing that could be confirmed and that
showed segregation with the phenotype (Table 2). Both
mutations are predicted to be pathogenic by SIFT, Muta-
tionTaster, and Polyphen2 and have CADD scores > 20
(Table 2). Variant c.988C > T was found in 3/243,112
alleles and c.822_823dup in 57/277,136 alleles in the
Genome Aggregation Database (gnomAD), all of them
from European populations, but were not present in
the dbSNP (build 138), 1000 Genomes Project, the
NHLBI Exome Variant Server, The Greater Middle
East (GME) Variome Project, or in our in-house data-
bases. The duplication of two base pairs predicts a
premature stop codon upstream of the galactosyl-
transferase domain (Fig. 1d). This could lead to a
decrease in the transcript carrying this mutation due
to nonsense-mediated RNA decay or to a truncated
variant of the B3GALNT2 protein that lacks the func-
tional galactosyltransferase domain. The missense
mutation is located in a conserved region within the
galactosyltransferase domain (Fig. 1d) and could
therefore affect the biochemical activity of
B3GALNT2.
Family B
In order to map the chromosomal location of the disease
gene in the extended family, we carried out a homozygos-
ity mapping approach using whole genome SNP genotyp-
ing data from four affected and two unaffected
individuals, assuming that a homozygous mutation is
responsible. Homozygosity analysis yielded a single ~
3.9 Mb homozygosity-by-descent interval defined by
flanking heterozygous SNP markers at positions
232,153,793 (rs1475514) and 236,077,778 (rs4660126)
(human version GRCh38/hg38) on chromosome 1q42.2-
q42.3 (LOD Score: 3.6). Copy number variation (CNV)
analysis of microarray SNP genotyping did not detect any
potentially pathogenic aberrations in the patients. The
region of homozygosity contains 14 protein-coding genes
(Table 3) and none of these genes had previously been
implicated in autosomal recessive ID (ARID). However,
the B3GALNT2 is contained within this locus, and as
mutations in this gene give rise to congenital muscular
dystrophy-dystroglycanopathy, together with brain and
eye anomalies and ID as prominent features it was further
investigated. Exome sequencing data available from indi-
vidual V:2 identified a novel homozygous missense muta-
tion, c.979G >A in exon 8 of B3GALNT2 that is predicted
to be pathogenic by PolyPhen2, SIFT, PROVEAN, and
MutationTaster. The variant results in an asparagine to
aspartic acid substitution, p.Asp327Asn (D327N), at a
Table 3 The protein-coding genes within the mapped locus uncovered in Family B
Gene name Protein Disease association/mode of inheritance
LYST Lysosomal trafficking regulator AR-Chediak-Higashi syndrome
GNG4 Guanine nucleotide-binding protein -
B3GALNT2 Beta-1,3-N-Acetylgalactosaminyltransferase 2 AR-Muscular dystrophy-dystroglycanopathy
(congenital with brain and eye anomalies,
type A, 11
TBCE Tubulin-specific chaperone E AR-Encephalopathy, progressive, with
amyotrophy and optic atrophy
AR-Hypoparathyroidism-retardation-dysmorphism
syndrome
AR-Kenny-Caffey syndrome, type 1
GGPS1 Geranylgeranyl diphosphate synthase 1 -
ARID4B AT-rich interaction domain-containing protein B -
TOMM20 Translocase of outer mitochondrial membrane 20 -
IRF2BP2 Interferon regulatory factor 2-binding protein 2 -
TARBP1 TAR RNA-binding protein 1 -
COA6 Cytochrome c oxidase assembly factor 6 AR-Cardioencephalomyopathy, fatal infantile, due
to cytochrome c oxidase deficiency 4
KCNK1 Potassium channel, subfamily K, member 1 -
MAP3K21 Mixed-lineage kinase 4 -
SIPA1L2 Sipa1-like protein 2 -
DISC1 Schizophrenia 9 Susceptibility to schizophrenia
AR autosomal recessive
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highly conserved residue within the galactosyltransferase
domain of the protein [11]. The mutation was validated by
Sanger sequencing and co-segregated with the phenotype
in the kindred. It was found in 6/244,450 alleles in the
GnomAD database but it was not present in the dbSNP
(build 138), 1000 Genomes Project, the National Heart,
Lung, and Blood Institute (NHLBI) Exome Sequencing
Project (ESP), The Greater Middle East (GME) Variome
Project, or in our in-house databases of 500 exomes/ge-
nomes from unrelated individuals of Middle Eastern/Iran-
ian origin. No other likely candidate variants were
identified in exome data and inspection of all rare homo-
zygous variants did not reveal other persuasive candidates
in the linked locus.
Complementation assays
To test the potential pathogenicity of the identified muta-
tions and to compare their effect with previously described
B3GALNT2 mutations, complementation experiments
were performed. A previously generated B3GALNT2-defi-
cient haploid HAP1 cell line (ΔB3GALNT2) was used for
complementation with WT and mutant variants of
B3GALNT2 cDNA. To predict the effect on B3GALNT2
enzymatic activity, cells were stained with the IIH6 anti-
body, recognizing the ligand-binding glyco-epitope on α-
DG; subsequently cytometric analysis was performed.
B3GALNT2-deficient cells were largely devoid of IIH6
staining (Fig. 3a; 4.0% IIH6-positive cells), emphasizing
the importance of B3GALNT2 for O-mannosylation of
α-DG. Complementation of the B3GALTN2-deficient
cells with WT B3GALNT2 cDNA clearly restored IIH6
staining (Fig. 3b; 94.9% IIH6-positive cells). Complemen-
tation with B3GALNT2 cDNA containing the two base
pair deletion (p.Ile276LeuFs*26) failed to restore IIH6
staining (Fig. 3c; 3.6% IIH6-positive cells), indicating that
this mutation abolishes B3GALNT2 activity. In contrast,
complementation with B3GALNT2 cDNA containing
the missense mutation (p.Arg330Cys) significantly re-
stored IIH6 staining (Fig. 3d; 85.5% IIH6-positive cells as
compared to 94.9% for the WT construct), indicating
that this mutation only mildly affects B3GALNT2
activity.
Fig. 3 Complementation of B3GALNT2-deficient HAP1 cells. a–g IIH6 FACS analysis of HAP1 B3GALNT2-deficient cell lines (ΔB3GALNT2) (a) complemented
with WT (b) and different B3GALNT2 mutants (c–g). Percentages of IIH6-positive (upper right corner) and IIH6-negative (upper left corner) are given. The
fluorescent signal of WT cells incubated with only the secondary antibody was used to determine the percentage of IIH6-positive cells
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Furthermore, complementation with three previously
described missense mutations [10] was performed as a
comparison to the variants identified here. Remarkably,
complementation with B3GALNT2 cDNA harboring the
only homozygous missense mutation (p.Val268Met) that
was identified in Stevens et al. did restore IIH6 staining
completely (Fig. 3e; 97.2% IIH6-positive cells). Comple-
mentation with the two other B3GALNT2 mutants
(p.Gly247Glu and p.Arg292Pro), identified as compound
heterozygous variants in one patient, led to partial res-
toration of IIH6 staining (Fig. 3f, g; 72.8% and 70.8 IIH6-
positive cells, respectively), indicating that these variants
are not completely non-functional.
Discussion
In this report, we describe two families affected with ID
with and without epilepsy caused by mutations in
B3GALNT2, a known gene associated with MDDG. Re-
markably, the patients present with psychomotor and
speech delay, epilepsy, and behavior problems, but no
signs of muscular dystrophy and ocular problems, a pres-
entation not previously associated with MDDG syn-
dromes. Although late-onset manifestation of muscular
dystrophy in the presented cases, particularly the younger
individuals, cannot be excluded, the muscle defects are
typically more prevalent than structural brain anomalies
and cognitive impairments in previously reported forms of
MDDG [18–23]. Two of the patients from these two
families had signs of white matter signal intensity changes
at a younger age, but these were not seen at a later age.
Individuals reported with B3GALNT2mutations present
with severe phenotypes, characterized by cobblestone lis-
sencephaly, congenital muscular dystrophy, and other
features indicative of WWS or slightly milder MEB/FCMD-
like phenotypes [10]. Recently, a patient was reported with
a milder phenotype consisting of psychomotor retardation,
ataxia, spasticity, muscle weakness, white matter anomalies,
a hypoplastic pons, and subcortical cerebellar cysts [11].
Interestingly the phenotype, caused by a compound hetero-
zygous mutation (p.Asp327Asn/p.Glu65fs*; Fig. 4), includes
the p.Asp327Asn variant identified in the Iranian kindred
in the homozygous state.
The severity of the mutant B3GALNT2 phenotype can
only be partially explained by the pattern of mutations.
Biallelic loss-of-function (LOF) mutations are most com-
monly seen in association with a WWS phenotype, but
Fig. 4 Overview of known B3GALNT2 mutations, categorized by clinical phenotype. Effect of the underlined mutations was tested by the complementation
assay. The relative activity of tested mutations as determined in the complementation assay (Fig. 3) is indicated
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in one case also with an MEB/FCMD-like presentation
[10] (Fig. 4). Compound heterozygous missense muta-
tions are more often associated with an MEB/FCMD-like
disease. Remarkably, the combination of a missense mu-
tation and a frameshift mutation lead to a range of vari-
able phenotypes: WWS; MEB/FCMD-like; the mild
muscle-brain phenotype reported by Hedberg et al.; and
the mild phenotype without clear muscular involvement
reported in this manuscript.
To assess whether the variable phenotypes could be
explained by the LOF resulting from the various mutations
in B3GALNT2, we carried out complementation assays in
B3GALNT2-deficient HAP1 cells under the hypothesis that
severity of phenotype is associated with B3GALNT2
complete LOF. These experiments revealed that
B3GALNT2 cDNA containing the duplication predicted to
cause p.Ile276LeuFs*26 could not restore IIH6-binding,
confirming that it represents a LOF allele. Compound het-
erozygosity of this mutation and another predicted LOF
frameshift mutation (p.Val243Glufs*2) is associated with
WWS [10]. In the patient described here, the same muta-
tion is found in compound heterozygosity with a
p.Arg330Cys substitution. This mutation had a minor effect
on B3GALNT2 function, as this B3GALNT2 variant re-
stored IIH6-binding almost to the level observed for WT
HAP1 cells (85.5% IIH6-positive cells vs 94.9% in control).
These data suggest a correlation between residual
B3GALNT2 activity and phenotype. However, a possible
correlation cannot be extrapolated to the activity measure-
ments for all other reported mutations (Fig. 4). Comple-
mentation with B3GALNT2 cDNAs containing either of
the compound heterozygous missense mutations associated
with a MEB-FCMD-like phenotype (p.Gly247Glu and
p.Arg292Pro) showed a partly reduced restoration of the
IIH6-binding (72.8% and 70.8%, respectively). In addition,
complementation with the p.Val268Met mutation, which
was found in the homozygous state in a MEB/FCMD
patient, fully restored the IIH6-binding in the B3GALNT2-
deficient cells (97.2% IIH6-positive cells vs 94.9% in con-
trol). A striking observation therefore is that the percentage
of IIH6-positive cells is not strictly correlated to the severity
of the phenotype. One explanation for this is that there is
some redundancy for B3GALNT2 activity, which may lead
to a different disease threshold across different cell types
and tissues. Possibly, B3GALNT2 has greater redundancy
in muscle cells than in neuronal, which would be in
contrast to other enzymes involved in O-mannosylation of
dystroglycan, for which mutations seem to have a higher
threshold in neuronal cells as compared to muscle cells.
It is of note that α-DG skeletal muscle staining using the
IIH6 antibody also does not in all cases correlate with the
severity of the clinical phenotype, as was shown for patients
with a defect in FKTN or FKRP [24]. However, the severity
of the clinical phenotype of B3GALNT2 patients seems to
correlate well with IIH6 muscle staining. In the mildly
affected patients described in this study, no significant
reduction of IIH6 staining was observed and there was an
intact muscular structure (Fig. 1d). In MEB/FCMD-like
patients a strongly reduced IIH6 staining and an abnormal
muscular structure have been observed [10] and a reduced
IIH6 staining in combination with an intact muscle struc-
ture was observed for the mild muscle-brain patient [11].
Conclusions
We show that mutations in B3GALNT2 can give rise to
DD/ID without muscle involvement. This atypical
MDDG syndrome phenotype could be classified as a
novel form, which is expected to expand due to large
scale WES efforts in ID cohorts. This study therefore
broadens the spectrum of the MDDG syndromes and
highlights the potential for mutations in other MDDG
genes to lead to non-syndromic ID as well.
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